Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

Abstract Background Inhibitors targeting immune checkpoint were proved effective in cancer immunotherapy, such as PD-1/PD-L1 blockade. The novel immune checkpoint TIGIT/PVR plays critical roles in suppressing the anti-tumor effects of CD8+ T and NK cells, and dual blockade of TIGIT/PVR and PD-1/PD-L...

Full description

Bibliographic Details
Main Authors: Xiuman Zhou, Jiangfeng Du, Hongfei Wang, Chunxia Chen, Ling Jiao, Xiangrui Cheng, Xiaowen Zhou, Shaomeng Chen, Shanshan Gou, Wenshan Zhao, Wenjie Zhai, Junhui Chen, Yanfeng Gao
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Cell Communication and Signaling
Subjects:
PVR
TIGIT
Small molecule compound
Virtual screening
Liothyronine
Cancer immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12964-020-00638-2

Internet

http://link.springer.com/article/10.1186/s12964-020-00638-2

Similar Items